We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 31

EU Court of Justice Advocate General issues ruling on Stem Cell patentability
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom
  • August 7 2014

In a non-binding ruling, Advocate General Cruz Villalón of the EU Court of Justice has determined that unfertilized human ova whose division


Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • Australia, Canada, European Union, United Kingdom, USA
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


European Commission study recommends changes to medical device and drug laws
  • Shook Hardy & Bacon LLP
  • European Union
  • May 17 2012

The European Commission has issued a report that analyzes the European Union’s (EU’s) REACH regulation, which addresses the registration, evaluation, authorization and restriction of chemical substances, and identifies overlap with other EU laws


EU agency will reinstate Ranbaxy’s GMP certificate
  • Shook Hardy & Bacon LLP
  • European Union, India
  • June 12 2014

The European Medicines Agency (EMA) has reportedly concluded its investigation of alleged non-compliance with good manufacturing practice (GMP) at


R&D for new drugs to treat “neglected diseases” continues to lag
  • Shook Hardy & Bacon LLP
  • European Union
  • October 31 2013

European researchers writing in a medical journal have found that just 4 percent of new therapeutic products registered with drug regulatory


EU adds pharmaceuticals to water pollution watch list
  • Shook Hardy & Bacon LLP
  • European Union
  • July 11 2013

The European Commission (EC) has added 12 new substances to the European Union's (EU's) priority list of chemicals known to pose a risk to the safety


April vote scheduled before EU Parliament on clinical trial data accessibility
  • Shook Hardy & Bacon LLP
  • European Union
  • March 20 2014

The European Parliament has postponed until April 2, 2014, debate on amended draft legislation (20120192 (COD)) that would require phar- maceutical


EU Medicines Agency plans to appeal interim rulings on release of clinical trial data
  • Shook Hardy & Bacon LLP
  • European Union
  • May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European


EU adopts joint procurement agreement for pandemic vaccines
  • Shook Hardy & Bacon LLP
  • European Union
  • April 17 2014

The European Commission has approved a joint procurement agreement under which all European Union (EU) member states will be able to "procure


European Parliament approves second medicines R&D initiative
  • Shook Hardy & Bacon LLP
  • European Union
  • May 1 2014

With opposition from the Green group, the European Parliament has apparently approved the second Innovative Medicines Initiative (IMI2), a 3